following an abbreviated submission:
fluticasone propionate/ formoterol fumarate (Flutiform k-haler®) is accepted for use within NHSScotland.
Indication under review: for the regular treatment of asthma where the use of a combination product [an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA)] is appropriate:
• For patients not adequately controlled with ICS as ‘as required’ inhaled short-acting β2-agonist or
• For patients already adequately controlled on both ICS and a LABA
Flutiform k-haler is a breath-actuated inhaler that is bioequivalent to Flutiform metered-dose inhaler (pMDI) and costs the same.
Download detailed advice64KB (PDF)
- Medicine name:
- fluticasone/formoterol (flutiform k-haler)
- SMC ID:
- Indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting β2 agonist) is appropriate: • For patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short-acting β2 agonist. • For patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist. • flutiform k-haler) is indicated in adults and adolescents aged 12 years and above.
- Pharmaceutical company
- Napp Pharmaceuticals Ltd
- BNF chapter
- Submission type
- Abbreviated submission
- Date advice published:
- 11 June 2018